• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Activ Surgical raises $45 million Series B round to give surgeons eagle eyes

September 30, 2021 by David Barret Leave a Comment

Activ Surgical, a Boston-based digital surgery company, announced a $45 million Series B round on Thursday. The round comes during a critical year for Activ Surgical. It’s in the process of developing new tools that give surgeons the ability to see otherwise invisible structures, and has plans to roll out those tools in the coming months. 

The first of those tools is the company’s hardware component, called ActivSight, which allows surgeons to see things that would otherwise be invisible, like blood flow through microscopic vessels inside tissue. The hardware, which received FDA 510(K) clearance in April of 2021, fits between any type of endoscope and a white light camera system. 

With the push of a button, ActivSight already allows features like blood flow (usually invisible, unless injectable dyes are used) to light up like a Christmas tree. But unlike injectable dye methods, ActivSight can visualize blood flow in real-time (i.e the images of tissue change color if blood flow slows or stops). 

“It’s the only system in the world, that intraoperatively can visualize things like blood flow without the injection of any dyes,” says CEO Todd Usen. 

This most recent round, will be used to support the commercialization of ActivSight, which is expected to go live in hospital systems in seven states in Q4 2021 or into next year. It will also be used to help glean a CE certification – a marketing clearance that allows medical devices to be marketed in Europe – which will allow ActivSight to roll out in seven European countries in 2022. Finally, the round will support the buildout of Activ’s more ambitious AI-based projects, which will allow the ActivSight devices to identify even more key structures for surgeons who use it. 

The round of funding was led by Cota Capital. Incuding Cota Capital, the round will bring seven new investors to Activ Surgical: BAM Funds, Magnetar Capital, Mint Ventures, Castor Ventures, Dream One Vision and NVIDIA. The company has raised $77 million in funding so far. 

Activ Surgical first made headlines in 2016 for creating a robot that performed the first totally autonomous suturing of soft tissue. The company’s founder Peter Kim holds a patent for a type of robot assisted surgery himself. But despite this, the company isn’t focused on building robots. 

“While robots are great, they’re only used in about 10 percent of minimally invasive surgeries. A robot can reach things that a human can’t but, until this point, a robot cannot see anything that a human can’t,” Usen says. 

Instead, the company is investing in tools that make surgeons themselves more savvy. Usen likens ActivSight’s current approach to installing a rear view camera on a car. 

“Your rearview camera on your car can see things that you can’t down below, then it will start beeping. When a robot can start identifying things a human can’t, that’s when robotics will really take off. That’s what Activ is doing, and that’s what our our robotic partner surgeons are excited about.” 

ActivSight has already shown that it can be used in the operating room. It’s been tested in a clinical trial on 70 patients at the University of Texas Health Science Center and the University of Buffalo. The results of those trials have not yet been released, but the company expects to publish data from that trial in October, a company PR confirmed to TechCrunch. 

However, the ActivSight system has already gleaned FDA 510(k) clearance, which means it will be rolling out in several hospital systems this year. Those include seven systems in New York, Buffalo, Texas, Ohio and Florida. 

The commercial deployment of ActivSight is just the first step for Activ Surgical. The goal is to ultimately collect a unique intraoperative dataset based on surgeries completed with ActivSight.  Then, a software suite called ActivInsight, would analyze the data collected, and apply machine learning algorithms to help identify even more features that would otherwise be invisible to surgeons. 

“We have the most unique dataset anywhere in the world,” says Usen. 

 “From that we’re able to do autonomous annotation and label key structures. It’s collecting nerve identification, veins versus arteries, key critical structures – that information will be annotated and labeled using machine learning, and then fed back to anyone using the ActivInsight module on their scope.”

This machine learning application won’t be rolled out right away. Usen expects ActivInsight prototypes to be used in patients for the first time in 2022. 

With this round of funding, those first steps will be set in motion. 

Source Link Activ Surgical raises $45 million Series B round to give surgeons eagle eyes

David Barret
David Barret

Related posts:

  1. Tennis-U.S. Open day eight
  2. Australian court orders Allianz pay $1.1 million penalty for travel insurance sales
  3. What we can learn from edtech startups’ expansion efforts in Europe
  4. China Roundup: Beijing is tearing down the digital ‘walled gardens’

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • Scientists Perplexed By 407-Million-Year-Old Fossilized Plant That Doesn’t Follow The Fibonacci Sequence
  • This Giant Goldfish Hybrid Weighs As Much As A 10-Year-Old – A Stark Warning About Dumping Pets
  • Scientists Gave Mice Neanderthal And Denisovan Genes. The Results Were Intriguing
  • 2024 Saw Higher Levels Of Carbon Dioxide In The Atmosphere Than Ever Before
  • Halloween Fireballs Will Grace Our Skies As The Taurid Meteor Showers Arrive
  • Newly Discovered Hunting Megastructures Suggest Pre-Bronze Age Societies More Sophisticated Than Previously Thought
  • What Is Spectroscopy And Why Is It So Important To Science?
  • Parkinson’s “Trigger” Seen For The First Time: Scientists Image The Toxic Molecules Inside The Human Brain
  • What Flying Animals Exist That Are Not Birds?
  • DNA Evidence Uncovers Surprising Origins Of Native Americans
  • Single Gene Swap “Transfers A Behavior” Between Two Species For The First Time
  • Interstellar Object 3I/ATLAS Has A Rare “Anti-Tail”, New Observations Confirm
  • Asteroid Apophis: Animation Shows Asteroid’s Nail-Biting Close Approach To Earth In 2029
  • Titan Breaks A Key Chemistry Rule: What That Means For Alien Life
  • Scientists Studied “Chicago Rat Hole” – They Have Bad News, The South Atlantic’s Magnetic Field Weak Spot Is Growing, And Much More This Week
  • Could This Be The Real Reason Humans Survived And Neanderthals Died Out?
  • Newly Discovered Snail Species Named After Studio Ghibli Co-Founder Is A Hairy Beauty
  • 2025 SC79 Is The Second-Fastest Asteroid Ever Found – And Only The Second Within Venus’ Orbit
  • When Red Devil Spiders Arrived On A New Island, Their Genome Dramatically Shrank In Half
  • Is This The World’s Oldest Story? Ancient Human Tale About The Seven Sisters May Be From 100,000 BCE
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version